Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05481125 · ClinicalTrials.gov registry record · NA

Clareon Toric vs Eyhance Toric

A NA study of Cataract and Aphakia, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
203
Enrollment target
8
Study locations

NCT05481125: Completed NA study of Cataract and Aphakia, sponsored by Alcon Research.

NCT05481125 is a NA study of Cataract and Aphakia that has completed, run by Alcon Research. The registered enrollment target is 203 participants, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (10% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05481125, a NA study of Cataract and Aphakia, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
203 participants
Enrollment target
8
Study locations

Study Summary

The primary purpose of this study is to compare the Clareon/Clareon Toric Intraocular Lenses (IOLs) to the Eyhance/Eyhance Toric IOLs in binocular Best Corrected Distance Visual Acuity (BCDVA) at 3 months postoperative.

Primary Outcome

Visual acuity was tested at a distance of 4 meters using a refraction chart and the correction obtained from a manifest refraction. BCDVA was measured in logarithm minimum angle of resolution (logMAR) units, with 0.00 logMar equating to 20/20 Snellen, which is considered normal distance eyesight. A lower logMAR value (more negative value) indicates better eyesight. This was a subject based assessment, and subject assigned a single score for both eyes.

Conditions Studied

Interventions

  • DEVICE Eyhance IOL
  • DEVICE Clareon IOL
  • DEVICE Clareon Toric IOL
  • DEVICE Eyhance Toric IOL
  • PROCEDURE Phacoemulsification surgery

Study Locations (8)

Texas

  • Houston Eye Associates - Houston
  • Berkeley Eye Center - Houston
  • Texas Eye Research Center - Hurst

New York

  • Seeta Eye Centers - Poughkeepsie

Ohio

  • Cleveland Eye Clinic - Brecksville

South Carolina

  • Carolina Eyecare Physicians, LLC - Mt. Pleasant

Tennessee

  • Vision for Life - Nashville

Utah

  • The Eye Institute of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2022-10-10
Est. Completion 2023-10-16
Phase NA
Alcon Research

275 total trials

What the finished NCT05481125 record still lists

NCT05481125 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (10% lower).

The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 5 interventions - of which Eyhance IOL is the first listed.

NCT05481125 lists 8 locations in 6 states (Texas, New York, Ohio).

Frequently Asked Questions

What is clinical trial NCT05481125 about?

NCT05481125 is a clinical study titled "Clareon Toric vs Eyhance Toric". The primary purpose of this study is to compare the Clareon/Clareon Toric Intraocular Lenses (IOLs) to the Eyhance/Eyhance Toric IOLs in binocular Best Corrected Distance Visual Acuity (BCDVA) at 3 months postoperative.

What is the current status of trial NCT05481125?

This trial is currently completed. It is a NA study. The enrollment target is 203 participants. The study started on 2022-10-10. Estimated completion is 2023-10-16.

What conditions does trial NCT05481125 study?

This clinical trial studies the following conditions: Cataract, Aphakia.

What interventions are being tested in trial NCT05481125?

The interventions under investigation include: Eyhance IOL (DEVICE), Clareon IOL (DEVICE), Clareon Toric IOL (DEVICE), Eyhance Toric IOL (DEVICE), Phacoemulsification surgery (PROCEDURE).

Who is sponsoring clinical trial NCT05481125?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05481125 being conducted?

This trial has 8 study locations across New York, Ohio, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05481125's enrollment target sits among peer trials

203 26th of 83 higher than 58 of 83 other Cataract trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05652686 · 203 participants · Phase 1

    A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • NCT06063122 · 203 participants · NA

    Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

  • NCT07031245 · 203 participants · NA

    Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05481125, the US trial registry maintained by the National Library of Medicine. NCT05481125 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.